

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Coliseum Capital Management, LLC</u>			2. Issuer Name and Ticker or Trading Symbol <u>BioScrip, Inc. [ BIOS ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>09/05/2017</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
<u>105 ROWAYTON AVENUE</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>ROWAYTON CT 06853</u>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/05/2017		S		221,829	D	\$3.08 <sup>(1)</sup>	4,514,103	I	See Footnotes <sup>(2)(3)</sup>
Common Stock	09/06/2017		S		1,349,475	D	\$2.96 <sup>(4)</sup>	3,164,628	I	See Footnotes <sup>(2)(3)</sup>
Common Stock	09/07/2017		S		1,275,637	D	\$2.88 <sup>(5)</sup>	1,888,991	I	See Footnotes <sup>(2)(3)(6)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Coliseum Capital Management, LLC

(Last) (First) (Middle)  
105 ROWAYTON AVENUE

(Street)  
ROWAYTON CT 06853

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Shackelton Christopher S

(Last) (First) (Middle)  
105 ROWAYTON AVENUE

(Street)  
ROWAYTON CT 06853

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Coliseum Capital, LLC

(Last)	(First)	(Middle)
<u>105 ROWAYTON AVENUE</u>		
<hr/>		
(Street)		
<u>ROWAYTON</u>	<u>CT</u>	<u>06853</u>
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

COLISEUM CAPITAL PARTNERS, L.P.

---

(Last)	(First)	(Middle)
<u>105 ROWAYTON AVENUE</u>		
<hr/>		
(Street)		
<u>ROWAYTON</u>	<u>CT</u>	<u>06853</u>
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

Coliseum Capital Partners II, L.P.

---

(Last)	(First)	(Middle)
<u>105 ROWAYTON AVENUE</u>		
<hr/>		
(Street)		
<u>ROWAYTON</u>	<u>CT</u>	<u>06853</u>
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

Gray Adam

---

(Last)	(First)	(Middle)
<u>105 ROWAYTON AVENUE</u>		
<hr/>		
(Street)		
<u>ROWAYTON</u>	<u>CT</u>	<u>06853</u>
<hr/>		
(City)	(State)	(Zip)

**Explanation of Responses:**

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.04 to \$3.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The Common Stock is held directly by (a) Coliseum Capital Partners, L.P. ("CCP") of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2" and, together with CCP, the "Funds"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, and (c) a separate account investment advisory client of CCM (the "Separate Account").
- Christopher Shackelton ("Shackelton") and Adam Gray ("Gray") are managers of and have an ownership interest in each of CCM and CC, and may be deemed to have an indirect pecuniary interest in the shares held by the Funds and the Separate Account due to CCM's right to receive performance-related fees from the Separate Account and CC's right to receive performance-related fees from the Funds. Each of Shackelton, Gray, CCP, CCP2, the Separate Account, CC and CCM disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.95 to \$3.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from from \$2.85 to \$2.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Following the transactions reported herein, CCP, CCP2 and the Separate Account directly owned 1,167,330; 260,942; and 460,719 shares of Common Stock, respectively.

**Remarks:**

Shackelton is a director of the Issuer. As a result, the following persons may be deemed directors by deputization of the Issuer solely for purposes of Section 16 of the Securities Exchange Act of 1934, as amended: CCM, CC, CCP, CCP2, and Gray.

Coliseum Capital Management, LLC, By: /s/ Thomas Sparta, Thomas Sparta, Attorney-in-fact 09/07/2017

Christopher Shackelton, By: /s/ Thomas Sparta, Thomas Sparta, Attorney-in-fact 09/07/2017

Coliseum Capital, LLC, By: /s/ Thomas Sparta, Thomas Sparta, Attorney-in-fact 09/07/2017

Coliseum Capital Partners, L.P., By: Coliseum Capital, LLC, its General Partner, By: /s/ Thomas Sparta, Thomas Sparta, Attorney-in-fact 09/07/2017

Coliseum Capital Partners II, L.P., By: Coliseum Capital, LLC, its General Partner, By: /s/ Thomas Sparta, Thomas Sparta, Attorney-in-fact Adam Gray, By: /s/ Thomas Sparta, Thomas Sparta, Attorney-in-fact 09/07/2017

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**